Nat Commun: Multiple sclerosis drugs can be used to treat coronavirus infections.

Oct 4, 2020 /--- In a recent study, scientists found that an antiviral drug is effective in suppressing coronavirus replication that causes COVID-19, as well as in suppressing inflammatory responses caused by infection.
results were published recently in the journal Nature Communications.
a study led by Christian Kanstrup Holm and David Olagnier showed that a drug called fumarate methamphetide (DMF), approved for the treatment of multiple sclerosis patients, inhibits the growth of a range of viruses in human cells, including coronavirus (SARS-CoV2).
"We obviously don't know if the drug will work for human infection, it's up to infectious disease experts to test it," he said.
, I must say, I am very optimistic."
, an associate professor in the Department of Biomedical Sciences at Aolhus University in Denmark, said he and his colleague David Olagnier.
(Photo source: www.pixabay.com) The pandemic occurred when Christian Kanstrup Holm and his colleagues were testing the effectiveness of a drug that was actually the same as a special hardened drug called 4-cinkitaconate, which is used in such substances as herpes virus, smallpox virus (pox virus) and Zika virus.
Kanstrup Holm explains: "Because of the sudden emergence of coronavirus, we also tested it and saw great results.
the number of repetitions of coronavirus replicating itself in cells in the body has been greatly reduced.
, the drug suppresses immune responses or inflammation, which is known to be one of the most important risk factors for patient death."
when the team saw the results of chloric acid 4-sin esters, they repeated the experiment using the approved product, DMF, which showed the same inhibition.
(bioon.com) Source: Medicine for multiple sclerosis patients ats coronavirus-at least in a test tube Source: David Olagnier et al, SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-incy activity of of 4-octyl-itaconate and dimethyl fumarate, Nature Communications (2020). DOI: 10.1038/s41467-020-18764-3.